Online inquiry

IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5620MR)

This product GTTS-WQ5620MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5620MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ35MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ13238MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ4049MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ15811MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ1127MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ4608MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ8290MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ11971MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MM-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW